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Introduction
Epithelial ovarian cancer (OC) is considered a chemoresponsive tumor with high initial response rates to stan-
dard therapy consisting of  platinum/paclitaxel (1). However, most women with high-grade serous carcinoma 
(HGSC) eventually develop recurrence, which rapidly evolves into chemoresistant disease (2). Recurrent OC 
is incurable; therefore, novel strategies to prevent disease relapse and chemoresistance are needed.
It has been hypothesized that chemoresistant cancers are driven by cancer stem cells (CSCs) (3). Although 
chemotherapy effectively decreases tumor burden, it also contributes to enriching the population of  OC stem 
cells (OCSC) in residual tumors (4), supporting the concept that OCSC contribute to tumor relapse after ther-
apy. OCSC are characterized by expression of  specific cell surface markers (4–6) and the ability to self-renew, 
differentiate, and generate tumors when injected in small numbers (50–1,000 cells) in NOD/SCID mice (7). 
The most robust marker currently used to identify CSCs in ovarian tumors, as well as other solid tumors, 
remains aldehyde dehydrogenase (ALDH) activity (6). ALDH+ cells isolated from HGSC cell lines and pri-
mary human tumors (4, 6) displayed stem cell properties, including spheroid-forming and tumor-initiating 
capacity, enhanced drug resistance, upregulation of  stemness-associated transcription factors (e.g., Sox2, 
Nanog, Oct4), and expression and corresponding downregulation of  the expression of  differentiation-related 
genes HOXA10 and HOXA11 (4, 6). As a member of  the ALDH family of  detoxifying enzymes (8), ALD-
H1A1 has also been proposed as a functional regulator of  OCSC. ALDH1A has been shown to be essential 
for oxidation of  intracellular aldehydes (8) and is reported to play a key role in early differentiation of  stem 
cells through oxidation of  retinol to retinoic acid (9). Furthermore, therapies targeting ALDH1A1 appear to 
be a promising approach for eradicating CSCs and preventing chemoresistant tumor relapse (4).
In high-grade serous ovarian cancer (OC), chemotherapy eliminates the majority of tumor cells, 
leaving behind residual tumors enriched in OC stem cells (OCSC). OCSC, defined as aldehyde 
dehydrogenase–positive (ALDH+), persist and contribute to tumor relapse. Inflammatory cytokine 
IL-6 is elevated in residual tumors after platinum treatment, and we hypothesized that IL-6 plays a 
critical role in platinum-induced OCSC enrichment. We demonstrate that IL-6 regulates stemness 
features of OCSC driven by ALDH1A1 expression and activity. We show that platinum induces 
IL-6 secretion by cancer-associated fibroblasts in the tumor microenvironment, promoting OCSC 
enrichment in residual tumors after chemotherapy. By activating STAT3 and upregulating ALDH1A1 
expression, IL-6 treatment converted non-OCSC to OCSC. Having previously shown altered DNA 
methylation in OCSC, we show here that IL-6 induces DNA methyltransferase 1 (DNMT1) expression 
and the hypomethylating agent (HMA) guadecitabine induced differentiation of OCSC and reduced 
— but did not completely eradicate — OCSC. IL-6 neutralizing antibody (IL-6-Nab) combined with 
HMA fully eradicated OCSC, and the combination blocked IL-6/IL6-R/pSTAT3–mediated ALDH1A1 
expression and eliminated OCSC in residual tumors that persisted in vivo after chemotherapy. We 
conclude that IL-6 signaling blockade combined with an HMA can eliminate OCSC after platinum 
treatment, supporting this strategy to prevent tumor recurrence after standard chemotherapy.
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However, it has been recently recognized that differentiated cancer cells can acquire self-renewal and 
stemness properties under the influence of  extrinsic factors found in the tumor microenvironment (TME) 
(10). Proinflammatory factors in the TME recently reported to play a regulatory role in CSC proliferation 
include IL-1, -6, and -23 (11) and the transcription factor NF-κB (12). IL-6, a cytokine that stimulates cell 
proliferation and invasion, is enriched in OC-associated malignant ascites (12–14). Cancer associated fibro-
blasts (CAFs) in the ovarian TME serve as a reservoir for protumorigenic inflammatory cytokines, includ-
ing IL-6 (15, 16). It has been demonstrated that CAF-cancer cell crosstalk plays a key role in OC progres-
sion (17), maintaining an optimal microenvironment for OC cell survival and proliferation. Furthermore, 
platinum-DNA damage induced secretion of  IL-6 by OC cells and contributed to chemoresistance (18), 
suggesting an important connection between platinum activation of  the IL-6 signaling pathway and OC 
progression. In this regard, IL-6 has been hypothesized to create a protective niche, maintaining survival of  
residual tumor cells and consequently contributing to tumor relapse (16).
Epigenetic dysregulation that results from the reciprocal interplay between immune, stromal, and can-
cer cells plays a pivotal role in driving tumor initiation and tumor progression (19–22). Crosstalk between 
tumor cells and the microenvironment is mediated by both cell-to-cell contact and soluble substances, lead-
ing epigenetic alterations in both neoplastic and the surrounding nontumorigenic cells, including CAFs, and 
contributing to the formation of  a “cancer favorable niche” (19–21, 23). Extensive studies highlight that the 
epigenetic effects of  chronic inflammation and immune cells on tumor cells to increase tumorigenesis risk. 
Inflammation cytokine IL-6, in the context of  gastric cancer and colon cancer, induced upregulation of  DNA 
methyltransferase 1 (DNMT1), leading to DNMT-mediated gene silencing and tumorigenesis (19, 24, 25). 
Altered DNA methylation has been associated with CSC phenotype maintenance (4) and has been linked to 
the undifferentiated phenotype of  CSCs. We demonstrated that hypomethylating agents (e.g., guadecitabine, 
decitabine) inhibit stemness characteristics and tumor initiating capacity (4). In this regard, blocking IL-6 sig-
naling in combination with a hypomethylating agent (HMA) may be a promising approach to disrupt cross-
talk between tumor cells and their protective niche and to target OCSC. Early clinical trials using antibodies 
against human IL-6 (Siltuximab) or IL-6 receptor (IL-6R) (Tocilizumab) reported some activity as single 
agents (26), but convincing clinical activity has not yet been demonstrated (27), suggesting that rationally 
designed combinations should be investigated.
Here, we demonstrate that treatment of OC cells with platinum- or IL-6– induced pSTAT3 signaling, which 
upregulated ALDH1A1 expression, increased stemness-associated genes and DNMT1 and enriched the popu-
lation of ALDH+ cells. These cells displayed enhanced spheroid formation ability and increased resistance to 
platinum. Functional consequences of these molecular and cellular changes were further investigated using an 
in vivo model enriched in CSCs after platinum treatment. OCSC were targeted with an IL-6 neutralizing anti-
body (Nab) combined with the second-generation HMA guadecitabine. The combination treatment inhibited 
the stemness features of tumor cells persisting after chemotherapy and eradicated the ALDH+ population. These 
results support a combination between an epigenetic modulator and an anti–IL-6 antibody as a potentially novel 
strategy following chemotherapy with the goal of targeting surviving OCSC and preventing disease recurrence.
Results
IL-6 expression, OC progression, and reduced chemotherapy response. Inflammatory responses including IL-6–
mediated inflammation have been shown to contribute to OC progression and chemoresistance (12). Anal-
ysis of  the transcriptomic profiles of  high-grade serous ovarian cancer (HGSOC) tumors from The Cancer 
Genome Atlas (TCGA) data portal demonstrated that upregulation of  IL-6 expression was significantly 
associated with poor (<12 months) tumor-free survival (Figure 1A). Moreover, high IL-6 expression cor-
related (P = 0.0023) with reduced progression-free survival after initial chemotherapy (Figure 1B). In a pan-
el of  OC cell lines, we examined expression of  IL-6 and IL-6R, IL-6 secretion in vitro by ELISA, and IL-6 
levels after treatment with an IC50 dose of  cisplatin (CDDP; Supplemental Table 1; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.122360DS1). Levels of  mRNA for 
IL-6 and IL-6R and basal IL-6 levels in conditioned media (CM) varied among the OC cell lines (Figure 2, 
A–D); however, CDDP treatment consistently increased (P < 0.01) IL-6 levels in CM (Figure 2D).
We further examined the association between increased IL-6, response to platinum treatment, and OC 
progression in vivo using an intraperitoneal xenograft model derived from platinum-sensitive A2780 OC 
cells. Mice were treated with vehicle or carboplatin (50 mg/ml weekly for 3 weeks), and blood and residual 
tumors were collected at sacrifice (day 21). Plasma IL-6 levels in carboplatin-treated mice were increased (P 
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< 0.001) compared with control (Figure 2E). In addition, increased (P < 0.05) expression of  IL-6 and IL-6R 
in tumor residuals from carboplatin-treated mice vs. vehicle-treated animals was observed (Figure 2F). Tak-
en together, these results demonstrated that platinum induces IL-6 secretion by OC cells and further suggest 
that platinum-induced IL-6 secretion contributes to enrichment of  OCSC in residual tumors.
Upregulation of  IL-6 signaling pathway regulates ALDH1A activity and OCSC formation. ALDH enzymatic 
activity is accepted as a marker of  OCSC (4), and aldefluor activity of  ALDH is determined primarily by 
ALDH1A1 isoform in OCSC (8, 28). We determine the percentage of  ALDH+ cells and ALDH1A1 mRNA 
expression in a panel of  OC cells. In whole-cell OC cultures, the percentage of  ALDH+ cells — determined 
by FACS analysis — ranged from 0.35%–45.6% (Supplemental Figure 1A), and ALDH1A1 expression 
varied from 0.1 pg/ml (OVCAR4) to 843.53 pg/ml (HeyA8) (Supplemental Figure 1B), with expression of  
ALDH1A1 and aldefluor activity being positively correlated in the majority of  OCs (Supplemental Figure 
1C) and suggesting that the ALDH1A1 is the main isoform contributing to aldefluor activity in OC cells.
To further investigate the functional role of  IL-6 signaling pathways in ALDH+ OCSC, we examined 
IL-6 secretion and expression levels in OC-derived ALDH+/– cells. In Kuramochi cells OVCAR4 and 
A2780, expression of  ALDH1A1 was greater (P < 0.01) in ALDH+ compared with ALDH– cells (Supple-
mental Figure 2A). The level of  IL-6 secreted in the growth media by ALDH+ cells was greater (P < 0.01) 
compared with respective ALDH– cells (Figure 3A), indicating that autocrine IL-6 secretion by ALDH+ 
cells correlated with OCSC phenotypes. Furthermore, expression of  IL-6 and IL-6R expression was 
increased (P < 0.05) in ALDH+ cells vs. respective ALDH– cells (Figure 3B). To further investigate the 
role of  ALDH1A1 or IL-6 in OCSC, we knocked down ALDH1A1 or IL-6 expression in Kuramochi OC 
cells (Supplemental Figure 2B) and examined the effect on ALDH cell populations by FACS analysis. As 
shown in Figure 3C and Supplemental Figure 2B, ALDH1A1 knockdown cells decreased the percent-
age of  ALDH+ cells compared with the scrambled shRNA control cells (Kuramochi, shALDH1A1_1, 
0.19% ± 0.2% vs. shcontrol 2.8% ± 0.2%; shALDH1A1_2, 0.35% ± 0.1% vs. shcontrol 2.8% ± 0.2%; 
OVCAR3, shALDH1A1_1, 5.84% ± 2.78% vs. shcontrol 37.04% ± 2.94%; shALDH1A1_2, 3.67% ± 
0.78% vs. shcontrol 37.04% ± 2.94%), confirming that expression of  ALDH1A1 was positively related to 
ALDH activity. ALDH1A1 knockdown decreased IL-6R and IL-6 expression (Supplemental Figure 2C). 
Similar results were found in OVCAR3 OC cells with a relatively high baseline level of  ALDH1A1 and 
IL-6 expression. ALDH1A1 knockdown in OVCAR3 decreased IL-6 expression, and IL-6 knockdown 
decreased ALDH1A1expression (Supplemental Figure 2D), further demonstrating that IL-6 and IL-6R 
expression correlated with ALDH1A1 expression in OC cells. Moreover, IL-6 knockdown reduced the 
percentage of  ALDH+ population ( Kuramochi, shIL-6_1, 0.79% ± 0.2% vs. shcontrol 2.8% ± 0.2%; 
shIL-6_2, 0.28% ± 0.1% vs. shcontrol 2.8% ± 0.2%; OVCAR3, shIL-6_1, 25.43% ± 2.33% vs. shcontrol 
Figure 1. Increased IL-6 expression after chemotherapy associated with cancer progression and poor clinical outcome. 
(A) Mean of IL-6 expression (reads per kilobase of transcript, per million mapped reads; RPKM) in patients with free tumor 
survival duration less than 12 months and more than 12 months after initial chemotherapy. Data was drawn from TCGA 
ovarian cancer portal. There are 20 patients with free tumor survival duration less than 12 months and 22 patients with 
free tumor survival duration more than 12 months after initial chemotherapy. (B) Survival probability of patients with 
high-grade serous ovarian cancer correlates with IL-6 expression levels in tumors after chemotherapy (P = 0.0023).
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Figure 2. Platinum-induced IL-6 secretion contributes to enrichment of OCSC in residual tumors. (A) Basal expression of IL-6 and (B) IL-6 receptor 
mRNA expression in human OC cells (ng/ml) were measured by qPCR. Bars represent average measurements of 3 independent experiments ± SD (n = 
3). (C) COV318, OVCAR4, Kuramochi, EFO-27, HeyA8, A2780_CR5, SKOV3, and A2780 OC cells were cultured under starving condition for 24 hours. ELISA 
was used to measure IL-6 levels in the conditioned media. IL-6 secretion (pg/ml/1 × 105 cells) was determined and normalized to the cell number (n = 3). 
(D) Kuramochi, OVCAR4, and A2780 OC cells were cultured under starving conditions for 24 hours and then treated with CDDP (IC50 or half of IC50). ELISA 
was used to measure IL-6 levels in the CM. IL-6 secretion (pg/ml/ 1 × 105 cells) was determined and normalized to the cell number. Average fold change of 
IL-6 secretion (± SD) of CDDP-treated cells compared with control-treated is shown (2-tailed Student’s t test, *P < 0.05, **P < 0.01, and ***P < 0.001) (n 
= 3). (E) Nude mice were bearing A2780 i.p.-derived xenograft tumors were treated with carboplatin (50 mg/kg, weekly for 3 weeks). Blood samples and 
xenograft tumors were collected after CDDP treatment. Average relative IL-6 expression level (± SEM) in the plasma compared baseline plasma IL-6 level 
was measured by IL-6 ELISA and shown (n = 6). (F) IL-6 and IL-6R expression in the tumor residuals treated with control and carboplatin were measured 
by using qPCR. Mean fold change of IL-6 and IL-6R expression of 6 independent experiments is reported. Two-tailed Student’s t test was used to analyze 
statistical significance (*P < 0.05, **P < 0.01, and ***P < 0.001).
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37.04% ± 2.94%; shIL-6_2, 16.70% ± 4.66% vs. shcontrol 37.04% ± 2.94% ) (Figure 3C and Supplemen-
tal Figure 2B) and ALDH1A1 protein expression (Supplemental Figure 2, C and D), supporting a reg-
ulatory role of  IL-6 in ALDH1A1 expression in OC cells. In addition, spheroid formation was reduced 
(P < 0.05) in Kuramochi cells with stable knockdown of  ALDH1A1 or IL-6 expression compared with 
scrambled shRNA (26 ± 3 vs. 19 ± 2 spheroids; 26 ± 3 vs. 13 ± 3 spheroids; Figure 3D), further support-
ing a role for ALDH1A1 and IL-6 in self-renewal and maintenance of  OCSC.
Figure 3. Upregulation of the IL-6 signaling pathway in ALDH+ ovarian cancer 
stem cells. (A) Five thousand ALDH+/– cells were FACS sorted from Kuramochi, 
OVCAR4, and A2780 cells into 96-well plates. IL-6 levels were measured by IL-6 
ELISA at 24 hours after starving conditions. Average relative IL-6 secretion levels 
(± SD) of ALDH+ OCs compared with ALDH– cells is shown (n = 3). (B) Expression 
of ALDH1A1, IL-6, and IL-6R were measured by qPCR in Kuramochi-, A2780-, and 
OVCAR4-derived ALDH+ cells, compared with respective ALDH– cells. Average fold 
change (± SD) of 3 independent experiments is shown. (*P < 0.05, **P < 0.01, and 
***P < 0.001) (n = 3). (C) Kuramochi cells were transfected with scrambled shRNA, 
shALDH1A1, or shIL-6 RNA. Side scatter of FACS analysis of the percentage of 
ALDH+ cell population in Kuramochi cells with stable ALDH1A1 and IL-6 knock-
down expression. Average percentage of ALDH+ cells (± SD) is shown below (n = 3, 
1-way ANOVA, *P < 0.05). (D) Representative pictures of spheroids formed by 500 
shcontrol, shALDH1A1, and shIL-6 knockdown Kuramochi cells, which were cul-
tured in stem cell culture condition for 14 days; the average number of spheroids 
(± SD) is shown below (n = 3, 1-way ANOVA, *P < 0.05). Scale bar: 100 μm.
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To further investigate downstream signals of  IL-6 regulation of  ALDH1A1 expression in OCSC, we 
examined STAT3 activation in ALDH+/– derived from OC cells. Compared with Kuramochi_ALDH– cells, 
the IL-6 signaling pathway was significantly upregulated in Kuramochi_ALDH+ cells, indicated by over-
expression of  IL-6R, pSTAT3, and downstream target gene cyclin D1 (Supplemental Figure 2E). IL-6 
knockdown in OC cells reduced expression of  ALDH1A1 and STAT3 (Supplemental Figure 2, C and D). 
Collectively, these results suggest that the IL-6 signaling pathway is upregulated in ALDH+ OC cells and 
plays a regulatory role in stem cell marker ALDH1A1 expression in OC cells.
Platinum and IL-6 induce ALDH1A1 and OCSC population. To determine whether IL-6 regulates ALDH1A1 
transactivation, we used an ALDH1A1 promoter luciferase reporter assay. Treatment with IL-6 transactivated 
the ALDH1A1 reporter gene expression in Kuramochi-derived ALDH– OC cells (Figure 4A), verifying the 
role of  IL-6 in regulation of  ALDH1A1 expression in OC cells. To further investigate the role of  CDDP-in-
duced IL-6 secretion in enrichment of  ALDH+ OCSC in OC, we examined aldefluor activity in OC cells 
treated with CDDP, IL-6, or IL-6-Nab. CDDP or IL-6 treatment alone increased the ALDH+ population 
(Kuramochi, Figure 4B; A2780, Supplemental Figure 3A), and the CDDP-induced increase was abrogated 
by IL-6-Nab treatment (Figure 4B, Supplemental Figure 3A).
Next, to examine if  CDDP- or IL-6–induced expression of  ALDH1A1 in ALDH– OC cells results in 
conversion of  aldefluor negative cells into aldefluor positive OCSC, Kuramochi ALDH– cells were treated 
with long-term CDDP or IL-6 (100 ng/ml, weekly for 3 weeks) and were analyzed by FACS. Either treat-
ment increased (P < 0.01) the ALDH+ population (1.37% ± 0.07% vs.0.47% ± 0.1%, CDDP vs. control; 
0.89% ± 0.13% vs. 0.47% ± 0.1%, IL-6 vs. control) (Figure 4C). To further verify the stemness features of  
CDDP- or IL-6–induced ALDH+ OC cells, spheroid formation assays were performed. IL-6–treated (100 
ng/ml, 3 weeks) A2780 ALDH– cells displayed enhanced (P < 0.05) self-renewal capability, as indicated by 
enhanced spheroid formation, compared with control-treated cells (Supplemental Figure 3B). After IL-6 
treatment (72 hours), a dose-dependence increase in the ALDH+ population in ALDH– cells was observed 
(Kuramochi, Supplemental Figure 3C; A2780, Supplemental Figure 3E), and increased (P < 0.05) expres-
sion of  stemness-associated genes Sox2 and Bmi1 in the converted cells was observed (Kuramochi, Supple-
mental Figure 3D; A2780, Supplemental Figure 3F). In addition, A2780 CDDP-resistant OC cells (CR5) 
were more mesenchymal in appearance compared with parental A2780 (Supplemental Figure 4A), con-
tained a greater percentage of  ALDH+ cells (Supplemental Figure 4B), and had higher mRNA expression 
of  ALDH1A1, IL-6, IL-6R, Sox2, and Bmi1 than parental OC cells (Supplemental Figure 4C). Furthermore, 
Kuramochi cells with acquired resistance to CDDP (Supplemental Figure 4D) displayed increased (P < 
0.05) constitutive expression of  ALDH1A1 (Supplemental Figure 4E), and CDDP treatment increased 
pSTAT3 and IL-6 protein levels (Supplemental Figure 4F), indicating that CDDP triggered activation of  
IL-6 signaling–mediated expression of  ALDH1A1 in OC cells. In platinum-sensitive OC cells, IL-6 treat-
ment activated STAT3, and the activation of  pSTAT3 upon transient IL-6 exposure was maintained up to 
12 hours (Supplemental Figure 4G). CDDP or IL-6 treatment increased (P < 0.05) mRNA expression of  
ALDH1A1, IL-6, and IL-6R (Supplemental Figure 4H) and ALDH1A1 protein level (Supplemental Figure 
4H) in platinum-sensitive OC cells — responses that were blocked by IL-6-Nab (Supplemental Figure 4, H 
and I). Taken together, these results indicate that CDDP-induced OCSC enrichment was partially due to 
IL-6 signaling pathway–mediated upregulation of  ALDH1A1 expression in OCs.
To further investigate downstream signaling involved in IL-6–induced upregulation of  ALDH1A1 
expression in OCs, we used a pSTAT3 inhibitor (Stattic) to functionally inhibit constitutive activation 
of  STAT3 in ALDH+ OCSC. Treatment of  Kuramochi-derived ALDH+ cells with Stattic decreased 
(P < 0.05) the percentage of  ALDH+ cells (Figure 4D) and inhibited pSTAT3-induced expression of  
ALDH1A1 (Figure 4E), confirming that IL-6 signaling pathway mediated upregulation of  ALDH1A1 
expression in OCs via activation of  STAT3.
IL-6-Nab–guadecitabine combination inhibits IL-6 signaling–mediated ALDH1A1 activation. The role of IL-6 in 
regulating DNA methytransferse–mediated gene silencing to promote tumorigenesis has been indicated in sol-
id tumors (24, 25). We found that IL-6 induced upregulation of DNMT1 expression in Kuramochi-derived 
ALDH– cells (Supplemental Figure 5A) and, correspondingly, that IL-6 knockdown reduced DNMT1 expres-
sion (Supplemental Figure 5B). Together with our previous findings on DNMT1, -3A, and -3B overexpression 
in ALDH+ cells compared with ALDH– cells, and considering the fact that the DNMT inhibitor guadecitabine 
induced differentiation of ALDH+ OC cells by upregulating differentiation genes HOXA10 and HOXA11 (4), 
we explored combining IL-6 blockade with DNMTi. To examine the effect of guadecitabine with IL-6-Nab on 
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Figure 4. CDDP-induced IL-6 regulates ALDH1A expression and OCSC enrichment. (A) OC-derived (Kuramochi-derived) ALDH– cells were cotransfected with 
pGL3-ALDH1A1-Luc and renilla luciferase plasmid vector (pRL) or pGL3-Luc and pRL. Transfected cells were cultured with starving medium for 24 hours and 
were then treated with IL-6 (100 ng/ml). Luciferase signals recorded 3 hours after drug treatment. Renilla luciferase activity used for normalization. Average 
fold changes (± SD) of relative luciferase unit (RLU) compared with pGL3 are shown (n = 3). (B) Quantification of FACS analysis of the percentage of ALDH+ in 
Kuramochi OC cells treated with CDDP (3 μM, 3 hours), CDDP+IL-6-Nab (1 μg/ml) and IL-6 (500 ng/ml) for 72 hours. Average percentage of ALDH+ cells (± SD) 
is shown on the graph, and the quantification is shown (n = 3, 1-way ANOVA, *P < 0.05 and ***P < 0.001). (C) Side scatter of FACS analysis of percentage of 
ALDH+ cells population in Kuramochi-derived ALDH– cells, which were treated with CDDP (IC50, weekly for 3 weeks) and IL-6 (100 ng/ml, weekly for 3 weeks). 
Average percentage of ALDH+ cells (± SD) is shown on the graph, and the quantification is shown (n = 3, 1-way ANOVA, **P < 0.01 and ***P < 0.001). (D) FACS 
analysis of the percentage of Kuramochi-derived ALDH+ cells treated daily with DMSO or Stattic (3 μM) for 3 days. Average percentage of ALDH+ cells ± SD is 
shown on the graph (n = 3). Two-tailed Student’s t test was used to analyze statistical significance (*P < 0.05). (E) Protein expression of ALDH1A1, DNMT1, 
pSTAT3, STAT3, and GAPDH in DMSO or Stattic-treated Kuramochi_ALDH+ cells were determined by Western blot (n = 2).
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OCSC, we treated Kuramochi_ALDH+ cells with guadecitabine, IL-6-Nab alone, or the combination with the 
hypomethylating agent. Guadecitabine decreased (P < 0.01) the percentage of ALDH+ cells (Figure 5A), and 
combining guadecitabine with IL-6-Nab further decreased (P < 0.05) the percentage of ALDH+ cells (Figure 
5A) and ALDH1A1 mRNA expression levels compared with either drug alone (Figure 5B). Similar results were 
observed in A2780 ALDH+ cells (Supplemental Figure 5, C and D). To further investigate the molecular mecha-
nism, ALDH+ cells sorted from Kuramochi and A2780_CR5 were treated with guadecitabine, IL-6-Nab, or the 
combination. Guadecitabine partially decreased expression of ALDH1A1 and DNMT1, and IL-6-Nab alone 
reduced pSTAT3 expression but had little effect on ALDH1A1 expression. The IL-6-Nab– guadecitabine com-
bination not only decreased endogenous expression of ALDH1A1, DNMT1, and pSTAT3 in ALDH+ OCSC 
(Figure 5C, Supplemental Figure 5E), but also markedly blocked CDDP-induced upregulation of ALDH1A1, 
DNMT1, pSTAT3, and IL-6 expression in Kuramochi OC cells (Supplemental Figure 5F).
Combining IL-6-Nab with the hypomethylating agent guadecitabine inhibits survival of  OCSC. Previous studies 
demonstrate that blocking IL-6 enhances the antitumor and apoptotic activity of  platinum chemotherapy 
in OC (29, 30) and inhibiting ALDH1A1 induces apoptosis of  OCSC (4, 31). To test the effect of  combin-
ing IL-6-Nab with guadecitabine on CDDP chemosensitivity and stem cell properties, clonogenic survival, 
apoptosis assays, and spheroid formation were performed using OC cells treated with a single agent (IL-6-
Nab, guadecitabine, CDDP) or in combination (IL-6-Nab + guadecitabine, CDDP + guadecitabine, CDDP 
+ IL-6-Nab, CDDP + IL-6-Nab + guadecitabine). IL-6-Nab or guadecitabine increased (P < 0.0001) CDDP 
chemosensitivity of  OC cells and decreased (P < 0.0001) the number of  surviving colonies (Supplemental 
Figure 6A). Combining guadecitabine with IL-6-Nab augmented (P < 0.0001) the cytoxic effect of  CDDP 
on OC clonogenic survival (Supplemental Figure 6A). To examine the effect of  these combination treat-
ments on self-renewal capability of  OC cells, spheroid formation assays using ultra-low attachment condi-
tions were performed on Kuramochi cells, followed by treatment with IL-6-Nab, guadecitabine alone, or in 
combination. Guadecitabine alone and with IL-6-Nab effectively reduced the numbers of  spheroids formed 
by OC cells (P < 0.05) but not IL-6-Nab alone (Figure 5D).
Next, we examined the effect of  guadecitabine and IL-6-Nab on ALDH+/– cells sorted from OC cells. 
Guadecitabine and IL-6-Nab had a greater effect on colony formation by ALDH+ cells compared with 
treatment with guadecitabine alone (Figure 5E and Supplemental Figure 6B), although guadecitabine 
inhibited (P < 0.05) clonogenicity ALDH+ compared with control treatment (Figure 5E and Supplemental 
Figure 6B). Guadecitabine alone or with IL-6-Nab resensitized ALDH+ cells to CDDP treatment (P < 
0.001), and the effect of  the combination therapy on resensitization of  ALDH+ cells to CDDP treatment 
was greater than either agent alone (Figure 5E and Supplemental Figure 6B). Guadecitabine or IL-6-Nab 
increased apoptosis in ALDH+ cells, indicated by caspase 3/7 cleavage activity (Supplemental Figure 6, 
C and D); however, greater (P < 0.001) cell death was induced by the combination of  guadecitabine with 
IL-6-Nab (Supplemental Figure 6, C and D). By inhibiting expression of  ALDH1A1 and blocking IL-6/
IL-6R/STAT3 signaling pathway activation, the IL-6-Nab–guadecitabine combination reduced OC cell 
survival, increased OC cell chemosensitivity, and induced apoptosis.
Combining IL-6-Nab with guadecitabine reduces platinum-induced enrichment of  OCSC in vivo and prevents 
tumor relapse. To investigate the efficacy of  IL-6-Nab plus guadecitabine as a potential postplatinum mainte-
nance strategy that prevents enrichment of  the ALDH+ stem cell population in vivo, we used an i.p. xeno-
graft model derived from OC cells (A2780). Nude mice bearing i.p. tumors were treated with carboplatin 
(50 mg/ml, weekly) for 3 weeks and were then randomized to a 2-week, twice-weekly treatment with vehi-
cle, IL-6-Nab, or guadecitabine alone or in combination (Figure 6A). Based on body weight measurements, 
single and combination treatments (chemotherapy followed by maintenance treatment) were well tolerated 
(Supplemental Figure 7A). Treatment with carboplatin effectively decreased (P < 0.001) total i.p. tumor 
weight and the number of  metastases (Figure 6, B and C, and Supplemental Figure 7, B and C). However, 
tumor relapse was observed 2 weeks after 3-week carboplatin treatment (Figure 6, B and C). Although 
guadecitabine treatment alone decreased (P < 0.05) recurrent tumor weight compared with vehicle-treated 
mice, the combination of  IL-6-Nab–guadecitabine was more effective (P < 0.05) at reducing platinum-treat-
ed recurrent tumor weight and metastases (Figure 6, B and C) and at preventing (P < 0.05) tumor relapse 
(Supplemental Table 2). IL-6-Nab alone had no effect on recurrent tumor growth (Figure 6B).
Xenograft tumors were collected and dissociated to single cell suspension at indicated time points 
(Figure 6A), and cells were analyzed for ALDH+ OCSC population by FACS and for self-renewal ability by 
the spheroid formation assay. Following carboplatin treatment, percentage of  ALDH+ cells was increased 
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Figure 5. IL-6-Nab–guadecitabine combination eliminates ALDH+ cells by inhibiting ALDH1A1 expression. (A) FACS analysis of the percentage of Kuramo-
chi-derived ALDH+ cells treated daily with guadecitabine (100 nM), IL-6-Nab (1 μg/ml), or IL-6-Nab– guadecitabine for 4 days. Average percentage of ALDH+ 
cells ± SD is shown on the side scatter graph (left), and the quantification is shown (right) (n = 3, 1-way ANOVA). (B) Average fold change of ALDH1A1 
expression ± SD in Kuramochi-derived ALDH+ cells treated with guadecitabine, IL-6-Nab, or IL-6-Nab–guadecitabine compared with control cells was deter-
mined by qPCR (n = 3, 1-way ANOVA, *P < 0.05 and ***P < 0.001) (C) Kuramochi-derived ALDH+ cells were treated daily with guadecitabine (100 nM), IL-6-
Nab (1 μg/ml), or IL-6-Nab–guadecitabine for 4 days. The protein expression of ALDH1A1, DNMT1, pSTAT3, STAT3, and GAPDH was determined by western 
blot (n = 2). (D) Spheroid formation assay of 500 conditioned Kuramochi cells, which were treated with control, IL-6-Nab (400 ng/ml), and guadecitabine 
(100 nM, 3 days) or in combination. Cells were directly sorted in 96 low-attached plates and cultured in stem cell condition for 14 days. Representative 
images and the average number of spheroids ± SD are shown in the graph. Scale bar: 100μm (n = 3, 1-way ANOVA, *P < 0.05). (E) Kuramochi_ALDH+ cells 
were treated daily with guadecitabine (100 nM), IL-6-Nab (1 μg/ml), or IL-6-Nab– guadecitabine for 4 days. Five hundred pretreated cells were reseeded 
into 6-well plates for clonogenic survival assays. Representative images and the average number and of colonies formed by pretreated Kuramochi_ALDH+ 
cells with the conditions described previously and pretreated Kuramochi_ALDH+ cells after exposure to cisplatin (3 μM) for 3 hours (n = 3, 2-way ANOVA, 
Dunnett’s and Sidak’s multiple comparisons tests used for multiple comparison, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001).
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(P < 0.001) in tumor residuals (carbo-residuals and carbo-recurrent) compared with control (Figure 6D and 
Supplemental Figure 8A). Maintenance treatment with guadecitabine alone or IL-6-Nab alone reduced (P 
< 0.001) the percentage of  ALDH+ cells in the tumor residuals, which was further decreased (P < 0.001) by 
IL-6-Nab–guadecitabine compared with either treatment alone (Figure 6D and Supplemental Figure 8A). 
OC cells isolated from carbo-residual and carbo-recurrent tumors demonstrated an enhanced (P < 0.001) 
ability to form spheroids compared with controls (Figure 6E and Supplemental Figure 8B), which was 
inhibited (P < 0.001) by maintenance treatment with guadecitabine or IL-6-Nab alone and further reduced 
by the combination therapy (Figure 6E and Supplemental Figure 8B).
In carboplatin-treated tumor residuals and recurrent tumors, increased (P < 0.05) expression of  IL-6, 
IL-6R, ALDH1A1, Sox2, and Bmi1 were observed (Figure 6F), supporting the possibility that platinum 
induces IL-6 signaling pathway–mediated ALDH1A1 expression in OC cells, resulting in enrichment of  
ALDH+ OCSC. Single-agent guadecitabine treatment decreased (P < 0.01) expression of  stemness genes 
(ALDH1A1 and Bmi1) and DNMT1 protein levels in recurrent tumors (Figure 6F and Supplemental 
Figure 8C). Maintenance treatment with IL-6-Nab decreased (P < 0.01) expression of  IL-6, IL-6R, ALD-
H1A1, Sox2, and Bmi1 (Figure 6F) and reduced protein levels of  ALDH1A1 and cyclin D1 (Supplemental 
Figure 8C). The negligible effect of  IL-6-Nab on STAT3 activation in recurrent tumors compared with 
vehicle-treated recurrent tumors was likely due to the short signal duration of  pSTAT3. However, down-
regulation of  cyclin D1 in IL-6-Nab–treated recurrent tumors further indicated the overall inhibition of  
the IL-6/IL-6R/STAT3 signaling pathway in IL-6-Nab–treated xenografts (Supplemental Figure 8C). 
The IL-6-Nab–guadecitabine combination (2 weeks of  treatment followed by 3-week carboplatin chemo-
therapy) markedly inhibited (P < 0.001) ALDH1A1, Sox2, Bmi1, IL-6, and IL-6R expression, along with 
DNMT1, ALDH1A1, pSTAT3, and CyclinD1 in recurrent tumors compared with vehicle treated tumors 
(Figure 6F and Supplemental Figure 8C). Carboplatin treatment increased (P < 0.05) human IL-6 levels 
in the circulation, which was reduced (P < 0.05) by either IL-6-Nab alone or IL-6-Nab–guadecitabine 
(Supplemental Figure 8D), suggesting that the anti-OCSC effect of  guadecitabine with IL-6-Nab was 
partially due to inhibiting IL-6 signaling pathways and DNMT1 expression.
Role of  the microenvironment in IL-6 secretion. The tumor-associated stroma including endothelial 
cells, fibroblasts, and adipocytes (23, 32, 33) serves as a reservoir for paracrine inflammatory factors, 
such as IL-6, contributing to the formation of  a favorable niche for CSC and maintenance and expan-
sion of  the OCSC population (23). To investigate the role of  the microenvironment in CDDP-induced 
IL-6 secretion, baseline IL-6 secretion level in normal omental fibroblasts (NOFs) growth media was 
examined. Basal IL-6 secretion by NOFs was significantly (P < 0.05) higher than OC cells (418.4 ± 
1.4 pg/ml/1× 105 NOF vs. A2780, 0.48 ± 0.01 pg/ml/ 1× 105 cells; Kuramochi, 1.35 ± 0.04 pg/ml/ 
1× 105 cells; OVCAR4, 51.3 ± 3.4 pg/ml/ 1× 105 cells) (Figure 7A). Furthermore, after CDDP treat-
ment, IL-6 secretion by NOFs was increased compared with nontreated cells (Figure 7B), indicating 
a potential role of  paracrine IL-6 from NOFs in contributing to OCSC enrichment. Moreover, CDDP 
induced IL-6 secretion by coculturing OC cells with NOFs (Figure 7B), suggesting the role of  NOFs 
in CDDP-induced IL-6 secretion. Finally, to further examine whether the microenvironment plays a 
role in cytokine IL-6 regulation of  ALDH1A1 expression in OCs, we cocultured OC-derived ALDH– 
cells (Kuramochi and A2780) with NOFs in a transwell cocultured system (Figure 7C). Coculture with 
NOFs increased endogenous mRNA expression of  ALDH1A1, Sox2, and Bmi1 in OC ALDH– cells 
compared with respective ALDH– cells cultured alone (Figure 7, D and E).
Discussion
It has been suggested that cellular plasticity allows nontumorigenic cancer cells, under environmental stimuli, 
to dedifferentiate and enter the CSC pool, contributing to therapy resistance and disease progression. Here, we 
demonstrate in mouse models replicating treatment and the clinical course of OC that platinum-induced acti-
vation of IL-6 signaling promotes enrichment in OCSC. We provide preclinical evidence for a potentially novel 
anti-IL6 + epigenetic intervention to eradicate OSCS in residual tumors. Our data have important consequences.
First, we show that both IL-6 and its receptor are highly expressed in ALDH+ OCSC compared 
with ALDH– non-OCSC, indicating the potential role of  IL-6 in regulation of  OCSC. In addition, we 
report that chemotherapy-linked inflammation, which was previously detected in clinical samples (14, 
34), is associated with upregulation of  IL-6, which in turn is associated with poor clinical outcome and 
low survival rate. Emerging evidence points to enrichment of  the OCSC population in residual tumors 
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Figure 6. Combination of IL-6 neutralizing antibody with gua-
decitabine as maintenance therapy reduces ALDH+ population 
in platinum-treated tumor residuals. (A) Schematic diagram 
of experimental design including carboplatin treatment phase 
followed by randomization to vehicle, guadecitabine, IL-6-Nab 
or the drug combination. (B–D) Effects of different treatment 
strategies on total tumor weight (n = 5, 1-way ANOVA, *P < 
0.05 and ***P < 0.001) (B), total number of tumor metastatic 
sites (n = 5, 1-way ANOVA, *P < 0.05) (C), and average of the 
percentage of ALDH+ cells in xenografts (n = 5, 1-way ANOVA, 
***P < 0.001) (D). (E) The average number ± SD of spheroids 
formed by 10,000 cells dissociated from xenografts, which were 
treated with vehicle, carboplatin, carboplatin + vehicle (Car-
bo_resi), carboplatin + guadecitabine, carboplatin + IL-6-Nab, 
or carboplatin + guadecitabine + IL-6-Nab (n = 5, 1-way ANOVA, 
**P < 0.01 and ***P < 0.001). (F) mRNA expression of ALDH1A1, 
Sox2, Bmi1, IL-6, and IL-6 receptor (n = 3, 1-way ANOVA, *P < 
0.05, **P < 0.01, and ***P < 0.001).
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after platinum therapy (4, 35). We and others have shown that increased IL-6 secretion in OC cells 
after platinum treatment contributes to chemoresistant OC (18, 30), and here we show a direct con-
nection between platinum-induced activation of  the IL-6 signaling pathway and OCSC enrichment. 
The molecular mechanism for IL-6 upregulation in OC cells upon cisplatin treatment is partially due 
to activation of  noncoding RNA HOTAIR, which has been demonstrated in our previous study. Plat-
Figure 7. Normal omental fibroblasts (NOFs) enhance IL-6 secretion. (A) Baseline 
IL-6 secretion level by Kuramochi, OVCAR4, A2780, and NOFs (n = 3). (B) NOFs cells 
were cultured alone or cocultured with OCs (Kuramochi + NOFs, OVCAR4 + NOFs, 
A2780 + NOFs) under starving condition for 24 hours and then treated with CDDP (IC50 
or half of IC50). IL-6 levels in the conditioned media were measured at 24 hours after 
exposure to CDDP by ELISA. IL-6 secretion (pg/ml/1 × 105 cells) was determined and 
normalized to the cell number. Average relative IL-6 secretion (± SD) of CDDP-treated 
cells compared with control-treated is shown in the graph (n = 3, 2-tailed Student’s 
t test, *P < 0.05, **P < 0.01, and ***P < 0.001). (C) Schematic diagram of transwell 
coculture system. In this 0.45-μm transwell coculture system, OC cells (Kuramo-
chi_ALDH–/A2780_ALDH– cells) with starving medium (DMEM supplemented with 
0.5% FBS) were seeded in the upper chambers alone (top) or with NOFs, which were 
seeded on the bottom chamber in DMEM supplemented with 0.5% FBS (bottom). (D 
and E) Average fold change with range of mRNA ALDH1A1, Sox2, and Bmi1 expression 
in (D) Kuramochi- and (E) A2780-derived ALDH– cells cocultured with NOFs compared 
with respective ALDH– cells alone shown in the graph (average fold change ± SD). Two-
tailed Student’s t test was used to analyze statistical significance (n = 3, *P < 0.05, 
**P < 0.01, and ***P < 0.001).
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inum-induced DNA damage results in upregulation of  HOTAIR expression, which in turn results in 
sustained activation of  DNA damage response after platinum treatment (36). We further showed that 
platinum-induced expression of  HOTAIR activated NF-κB activation during DNA damage response 
and upregulated downstream target gene IL-6 expression (36).
Second, we demonstrate that treatment-induced changes in stromal cells drive non-CSCs to CSC con-
version. The TME serves as a reservoir for inflammatory factors contributing to the formation of  a CSC 
favorable niche (23) and also plays an important role in regulating epigenetic events associated with CSC 
maintenance in tumors (37). Within the tumor sites, reciprocal crosstalk between immune, stromal, and 
cancer cells plays a crucial role in deregulating epigenetic-mediated gene silencing and driving tumor ini-
tiation and tumor progression (19–22). CAFs in particular (20, 22) are involved in inducing genome-wide 
methylation alternation required for epithelial-to-mesenchymal transition (EMT) and maintenance of  the 
stemness in prostate cancer cells (22). Along with fibroblasts, immune components — including myeloid 
and T cells, which secrete chemokines CXCL12, CXCL20 and CXCL8 — play key roles in maintaining the 
CSC niche (38, 39). It has been shown that coculture of  NOFs with OC cells converts NOFs into CAFs 
(17), and here we demonstrate a role for NOFs in platinum-induced IL-6 secretion and promoting enrich-
ment of  OCSC. Furthermore, recent studies highlight the epigenetic effects of  chronic inflammation and 
immune cells that promote tumorigenesis, including IL-6, which has been shown to upregulate DNMT1, 
leading to DNMT-mediated gene silencing and tumorigenesis in gastric and colon cancers (19, 24, 25). 
Here, we further demonstrate that IL-6 induced DNMT1 expression in OC cells, supporting the rationale 
to combine IL-6 signaling blockade with HMA to eliminate OCSC and prevents recurrent OC.
An emerging model based on recent findings that hierarchically organized cancer cell populations are 
more plastic than previously appreciated (35, 40) supports our findings that cancer cells may dedifferentiate 
and reenter the CSC pool under the influence of  extrinsic factors. Although IL-6 has been identified as an 
important regulator of  self-renewal of  CSCs in other tumor types (13, 32), the precise molecular mechanisms 
by which IL-6 regulate CSC in OC has not been clearly defined. Here, we demonstrate autocrine and para-
crine roles for IL-6 in regulation of  ALDH1A1 expression in OC cells. Expression of  IL-6 and/or IL-6R 
expression correlates with ALDH1A1 expression, and aberrant activation of  IL-6 signaling pathways in OC 
cells contributes the enrichment of  OCSC in tumors after platinum treatment. Further, the IL-6/STAT3 sig-
naling pathway is more activated in ALDH+ OC cells compared with ALDH– OC cells, and STAT3 phos-
phorylation is strongly associated with the expression of  ALDH1A1. Similar findings have been reported in 
colon (41) and breast (42) CSCs, indicating the role of  IL-6/STAT3 in maintenance of  ALDH+ CSCs and 
conversion of  non-CSCs into CSCs (43). STAT3 regulates ALDH1 expression in cancer cells by enhancing 
the binding of  transcription factor CCAAT enhance binding proteins β (CEBP/B) with ALDH1 promoter 
region (44, 45). Thus, targeting STAT3 activation–induced ALDH1A1 expression to eradicate OCSC has 
potential as a therapeutic strategy. These findings further support the possibility that inhibiting IL-6–induced 
activation of  STAT3 could provide a means of  targeting CSCs in OC. Anti–IL-6 antibody effectively blocks 
STAT3 activation by IL-6; however, IL-6-Nab treatment alone has not proven to be an effective therapeutic 
approach for advanced OC, suggesting that combinations with other targeted agents is necessary (27).
Epigenetic alterations play an important role in OCSC and OC chemotherapy resistance, being largely 
related to repression of  tumor-suppressor genes (specifically, chemotherapy-response and differentiation-as-
sociated genes) by DNA methylation (4, 46, 47). HMAs reverse the expression of  silenced tumor suppres-
sors and chemosensitize platinum-resistant ovarian tumors, resulting in significant clinical benefit (47–50). 
Importantly, epigenetic therapies, especially HMAs, have been demonstrated to reactivate epigenetic silenc-
ing in cancer immunotherapy, remove T cell repression, increase effector T cell tumor infiltration, inhibit 
tumor growth, and improve therapeutic efficacy of  immunotherapy, such as anti–PD-1/PD-L1 (51, 52) and 
NY-ESO-1 vaccine therapy (53). We have previously shown that ALDH+ OCSC harbor aberrant DNMT sig-
natures and examined the effects of  low-dose guadecitabine on OCSC. We found that this HMA reduces the 
OCSC population by driving these cells toward differentiation (4). Those results and the previous findings that 
blockade of  the IL-6/STAT3 signaling pathway induced apoptosis and resensitized OC cells to chemotherapy 
(30, 54, 55) support a combination strategy between an HMA and a STAT3 inhibitor, as we tested here.
The expression of  ALDH isoforms, which are responsible for the aldefluor activity, is cell type depen-
dent. Our group and others have shown the expression of  ALDH1A1 isoform is correlated to enzymatic 
activity in the majority of  OC cells (31, 56). However, this does not appear to be the case for some OC 
cells, including OVCAR4, as the dominant isoform for ALDH enzymatic activity in this cell lines is not 
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ALDH1A1 but, instead, other ALDH1 isoforms (ALDH1A2 and ALDH1A3). Although there was no 
correlation between expression of  IL-6 and IL-6R with ALDH1A1 expression in OVCAR4 cells, IL-6 and 
IL-6R significantly correlated with ALDH enzymatic activity (Supplemental Figure 1A), which determines 
stemness phenotypes. However, transcription factor CEBP/B binding sites are present in the promoter 
region of  ALDH1 isoform genes, indicating a similar mechanism of  regulation.
It has also been widely demonstrated that STAT3 regulates ALDH1 expression in cancer cells by enhanc-
ing the binding of  transcription factor CEBP/B with the ALDH1 promoter region (44, 45). Moreover, in 
Figure 2B, we show that IL-6/IL-6R expression is higher in OVCAR4-derived ALDH+ cells compared with 
ALDH– cells, which is consistent with our conclusion that expression of  IL-6/IL-6 R correlates with stemness 
phenotypes, detected by aldefuor activity, in OC cells.
Here, we show that the combination of  guadecitabine with IL-6-Nab was more effective than either treat-
ment alone at preventing tumor relapse after platinum therapy. IL-6-Nab alone had no significant impact on 
recurrent tumor growth, but IL-6-Nab–guadecitabine effectively decreased the ALDH+ OCSC population. 
Interestingly, the anti-OCSC effects of  IL-6-Nab were more apparent in vivo than in the 2-dimensional culture 
OC cells, supporting a combined effect on cancer cell and on components of  the TME. These results strongly 
support future clinical testing of  this combination as a posttreatment strategy in OC.
In conclusion, we demonstrate that IL-6 secreted by fibroblasts after platinum treatment promotes 
enrichment of  OCSC. Maintenance treatment with IL-6-Nab–guadecitabine after carboplatin inhibited 
OCSC enrichment by both inhibiting DNMT expression and blocking pSTAT3-mediated ALDH1A1 tran-
scription. The significance of  the study lies in the concept of  a potentially novel maintenance therapy in 
platinum-treated tumor residuals and recurrent tumors, based on the anti-OCSC effect of  this combination 
therapy. These results propose a new combination of  IL-6-Nab and epigenetic therapy as a maintenance 
strategy after chemotherapy for eradicating OCSC and preventing tumor recurrence.
Methods
Cell lines, culture conditions, and reagents. Human epithelial OC cell lines were maintained in the indicated media 
(Supplemental Table 3) at 30°C and 5% CO2. NOFs were isolated from omentum of noncancer patients and 
maintained in DMEM/F12 with 1% MEM vitamins, 1% MEM nonessential amino acids, and 1% penicil-
lin-streptomycin. All cell lines were authenticated in 2017 by ATCC and tested for mycoplasma contamination. 
Reagents are described in Supplemental Methods.
Aldefluor assay and flow cytometry. ALDH1 enzymatic activity was measured using the Aldefluor assay 
kit (Stemcell Technologies) following the manufacturer’s instructions, as described in our previous study (4).
Quantitative PCR (qPCR). Cultured cells were directly lysed in the RLT buffer (RNeasy Lysis Buffer, Qia-
gen). RNA was isolated by using AllPrep DNA/RNA/Protein Mini kit (Qiagen) following the manufactur-
er’s protocol. cDNA was transcribed from total RNA (from 100 ng–2.5 μg) by using SuperScript VILO cDNA 
synthesis kit (catalog 11754-010, Thermo Fisher Scientific), following the manufacturer’s instructions. qPCR 
was performed using LightCycler 480 SYBR Green I Master kit (Roche Diagnostics), and mRNA expression 
level was determined using LightCycler software version 3.5 (Roche Applied Science) and normalized to 
EEF1A. Primer sequences for qPCR (Thermo Fisher Scientific) can be found in Supplemental Table 4.
Clonogenic survival assay. Colony formation assay was performed on OC cells, as described in Supple-
mental Methods.
Transfection assays. Kuramochi and A2780 cells were seeded and grown into 6-cm well plates to 70% 
confluence in RPMI media supplemented with 10% FBS; they were then transfected with shALDH1A1 
plasmid DNA, shIL-6 plasmid DNA (6 μg, Santa Cruz Biotechnology Inc.), or scrambled control DNA 
oligos (6 μg) for 48 hours using Turbofect (Thermo Fisher Scientific), according to manufacturer’s protocol. 
Single, stably transfected colonies were selected by using puromycin antibiotic.
Human IL-6 ELISA and cytokine release assays. Cells were washed with PBS and then cultured in 
serum-starving media with 0.5% FBS prior to any treatment. CM was collected at indicated time points 
after treatment withdrawal. Cells were also collected, and the total number of  cells was determined. IL-6 
secretion levels in CM were measured by using human IL-6 ELISA Ready-SET-Go kits eBiosciences (cat-
alog 88-7066-86) and normalized to the cell number (pg/ml/1 × 105 cells). Global cytokine expression in 
CM was measured by using cytokine release assay (R&D Systems, catalog ARY005).
Spheroid formation assay. Spheroid formation assay was performed on OC cells and xenogtaft disassoci-
ated tumors, as described in the Supplemental Methods.
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Western blotting. Cells were lysed in RIPA lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM 
EDTA, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with (1×) protease inhibitors 
(MilliporeSigma). Xenograft tumors were lysed in RIPA buffer with protease inhibitors and homogenized 
using Rino tissue homogenization beads lysis kits as described above. Protein was isolated subject to West-
ern blot as described (18). Antibodies used for Western blotting are described in Supplemental Methods.
In vivo xenograft experiments. Athymic, BALB/c-nu/nu mice (Female nude; 6 weeks old; Harlan) were 
injected i.p. with 2 × 106 (A2780) cells. Three days after injection, mice were i.p. treated with carboplatin 
(MilliporeSigma) at 50 mg/kg, or PBS (n = 6 animals per group) weekly for 3 weeks. For the maintenance 
study, after 3 weeks of  carboplatin treatment, mice were randomized to receive guadecitabine (2 mg/kg) 
s.c., mouse IgG (5 mg/ml, InvivoGen), IL-6-Nab (IL-6-Nab; 5 mg/kg, InvivoGen) (i.p.) alone or in combi-
nation with guadecitabine, or vehicle (diluent) twice a week for 2 weeks. Mice were euthanized, and perito-
neal tumors were counted and weighed at the end of  the study. Tumors and blood samples were processed 
as described in Supplemental Methods.
Statistics. All experiments were performed in triplicate, and mean values ± SD of  biological triplicate 
measurements were calculated. Western blots were performed with biological duplicates, and representa-
tive images are presented in the figures. Two-tailed Student’s t test was used to statistically analyze the sig-
nificant difference between 2 groups by using Prism 4.0 (GraphPad Software), with a P value of  0.05 being 
considered statistically significant. One-way and 2-way ANOVA including Dunnett’s and Sidak’s multiple 
comparisons tests were used for multiple comparisons by using Prism 4.0, as well. A P value of  0.05 was 
considered statistically significant.
Study approval. All animal studies adhered to ethical regulations and protocols approved by the IACUC 
of  Indiana University (Indianapolis, Indiana, USA). The IRB of  Indiana University approved this research, 
and informed consent was obtained from all patients.
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